'Fasting pathway' points the way to new class of diabetes drugs

In liver cells, so-called class II HDACs (shown in green) are usually sequestered in the nucleus. Credit: Images: Courtesy of Maria Mihaylova, Salk Institute for Biological Studies.

A uniquely collaborative study by researchers at the Salk Institute for Biological Studies uncovered a novel mechanism that turns up glucose production in the liver when blood sugar levels drop, pointing towards a new class of drugs for the treatment of metabolic disease.

Their findings, published in the May 13, 2011, issue of the journal Cell, revealed a crucial role for so called histone deacetylases (HDACs), a group of enzymes that is the target of the latest generation of . HDACs get sugar production rolling when blood levels run low after prolonged periods of fasting or during the night.

"In , so-called class II HDACs are usually sequestered outside the nucleus but in response to fasting signals they quickly shuttle into the nucleus where they help turn on genes needed for glucose production," says Howard Hughes Medical Institute early career scientist Reuben J. Shaw, Ph.D., an assistant professor in the Molecular and Cell Biology Laboratory. "Thus drugs that specifically inhibit HDACs involved in gluconeogenesis may be very useful for the treatment of diabetes and metabolic syndrome."

A delicate and tightly regulated balance between de novo glucose production in liver and caching surplus glucose in muscle and fat tissue keeps our blood sugar levels from fluctuating erratically and causing irreparable damage to cells and tissues in the body.

After a meal, insulin instructs to squirrel away glucose for later use and turns off sugar production in the liver ensuring that blood sugar levels don't rise too high. Conversely, the fasting hormone glucagon signals liver cells to flip on glucose production when supplies run low.

In many patients with , however, the body turns a deaf ear to insulin's urgent message and as a result the liver acts like a sugar factory on overtime, churning out glucose throughout the day, even when are high. The most widely used drug to control blood glucose levels in type II diabetics is currently metformin.

"Metformin is originally derived from a plant found in Western Europe called 'French lilac' or 'Goat's Rue' because goats didn't like to eat it," says Shaw. "They steered clear of the plant because it contains a compound that acts to naturally lower blood glucose in animals that eat it-to prevent them from eating it again."

In response to glucagon, HDACs quickly move into the nucleus, where they help turn on genes needed for the production of glucose in the liver. Credit: Images: Courtesy of Maria Mihaylova, Salk Institute for Biological Studies.

A few years ago, Shaw had discovered how metformin helps insulin to control glucose levels. It binds to a "metabolic master switch" known as AMPK that blocks in the liver. Trying to identify novel targets of AMPK that might be relevant to diabetes Maria Mihaylova, a graduate student in the Shaw laboratory, focused her efforts on a family of HDACs known as class II HDACs. They function as negative regulators of gene activity by stabilizing the tightly coiled structure of DNA in chromosomes, making it inaccessible to proteins that transcribe DNA.

"We identified class II HDACs as direct targets of AMPK in a bioinformatics-based screen, but we didn't know which genes they might regulate in liver since they weren't even known to be found there," says Mihaylova. Working closely with Howard Hughes Medical Institute Investigator Ronald M. Evans, a professor in the Salk Institute's Gene Expression Laboratory, and his team, Mihaylova found that inhibiting class II HDACs shut down genes encoding enzymes needed to synthesize glucose in liver.

In collaboration with her colleagues in Marc Montminy's lab, a professor in the Clayton Laboratories for Peptide Biology and like Shaw and Evans a member of the Center for Nutritional Genomics at the Salk Institute, Mihaylova discovered that HDACs themselves associated with the DNA regulatory elements controlling the expression of the glucose synthesizing enzymes, but they only flocked there after she had treated cells with the fasting hormone glucagon.

"In response to the glucagon, chemical modifications on class II HDACs are removed and they can translocate into the nucleus," she explains. There, they bind to FOXO, a key metabolic regulator, which had been shown previously to be shut down by insulin.

"It came as a big surprise that FOXO is activated by glucagon," explains Shaw. Further experiments confirmed that the genetic suppression of class II HDACs in liver cells led to an increase in acetylated FOXO, which now can neither bind DNA nor activate the genes encoding glucose-synthesizing enzymes.

A parallel study, led by Montminy and published in the same issue of Cell as Shaw's paper, shows that in fruit flies, FOXO not only controls the expression of a fat-digesting enzyme but is activated by a glucagon-like hormone in a manner similar to human FOXO. "The central circuitry of how animals regulate metabolism in response to fasting and feeding is conserved from fly all the way to man emphasizing the importance of class II HDACs in coordinating how different hormones direct the creation and use of glucose," says Shaw, who is a co-author on Montminy's paper.

Up to this point, all experiments had been performed in cultured cells but Shaw and this team were really interested in whether class II HDACs controlled in mouse models of diabetes. Strikingly, suppression of all three HDACs simultaneously restored to almost normal in four different models of type 2 diabetes.

"These exciting results show that drugs that inhibit the activity of class II HDACs may be worthwhile to be pursued as potential diabetes drugs," says Shaw. Recently, many drug companies have been developing HDAC inhibitors as anti-cancer drugs, so Shaw speculates that some of these compounds, which may or may not be useful for cancer, could have therapeutic potential for the treatment of insulin resistance and diabetes.

"The key will be to specifically block HDACs involved in glucose control," he says "but the fact gluconeogenesis takes place in the liver makes this task easier as most drugs sooner or later travel to the liver once they hit the bloodstream." Shaw next plans to test whether these glucose loving HDACs may also play roles in certain forms of cancer as well.

Related Stories

Bypassing the insulin highway

date Apr 28, 2008

An immune cell known as a neutrophil releases a protein that can suppress glucose production in the liver –without targeting insulin, researchers have found.

Regulating the sugar factory in diabetes

date May 21, 2009

Scientists in Sydney and Boston believe they may have identified a gene that controls abnormal production of sugar in the liver, a very troublesome problem for people with diabetes.

SRC-1 controls liver's 'sweet spot' for glucose production

date Nov 30, 2010

SRC-1 (steroid receptor coactivator) orchestrates glucose production in the liver, regulating the activity of a cascade of enzymes that turns sugar production on and off in the liver, said Baylor College of Medicine and Duke ...

Blood sugar's manufacture limited by building blocks' supply

date Apr 03, 2007

Researchers have discovered a factor that controls blood sugar's manufacture in a novel way: by limiting the supply of its building blocks. The findings are reported in the April issue of the journal Cell Metabolism, publis ...

Old diabetes drug teaches experts new tricks

date May 14, 2009

Research from the Johns Hopkins Children's Center reveals that the drug most commonly used in type 2 diabetics who don't need insulin works on a much more basic level than once thought, treating persistently elevated blood ...

Recommended for you

Researchers reveal a genetic blueprint for cartilage

date Jul 02, 2015

Cartilage does a lot more than determine the shapes of people's ears and noses. It also enables people to breathe and to form healthy bones—two processes essential to life. In a study published in Cell Re ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.